title: Lansoprazole capsules and amoxicillin oral suspension in the treatment of peptic ulcer disease.
abstract: BACKGROUND
  Lansoprazole is a potent antisecretory drug also possessing anti-Helicobacter pylori activity in vitro. It is a candidate drug for combination regimens with antibiotics for treating H. pylori infections.
  
  
  METHODS
  In a semiblind study, 65 patients with duodenal and/or gastric ulcer and pathologic 14C urea breath test results were treated with either 60 mg lansoprazole every morning only for 14 days or combined with 500 mg amoxicillin oral suspension four times daily between meals, given for 11 days. Endoscopy and breath test were repeated after 6 weeks and 6 months. Patients with unhealed ulcers were withdrawn.
  
  
  RESULTS
  Eradication of H. pylori infection was attained in 46% of patients receiving lansoprazole and amoxicillin but in no patient receiving lansoprazole alone. Ulcers healed significantly more often in those who were H. pylori-negative (18 of 19 (95%)) than in those who were H. pylori-positive (20 of 41 (49%)). Adverse events, particularly stomatitis/sore throat and diarrhea, occurred significantly more often when amoxicillin was combined with lansoprazole.
  
  
  CONCLUSIONS
  Lansoprazole eradicated H. pylori infection only when combined with amoxicillin. Eradication rates in this study are hardly acceptable, and further studies are necessary to define optimal doses and duration of treatment. Using amoxicillin as an oral suspension may not be of any substantial benefit and may cause stomatitis and sore throat.
authors.affiliation: Medical Dept. A, Haukeland Hospital, University of Bergen, Norway.
authors.forename: J G
authors.initials: JG
authors.lastname: Hatlebakk
authors.forename: L B
authors.initials: LB
authors.lastname: Nesje
authors.forename: T
authors.initials: T
authors.lastname: Hausken
authors.forename: C J
authors.initials: CJ
authors.lastname: Bang
authors.forename: A
authors.initials: A
authors.lastname: Berstad
mesh_terms: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000284:Administration, Oral; D000658:Amoxicillin / Q000008:administration & dosage* / Q000009:adverse effects; D000897:Anti-Ulcer Agents / Q000008:administration & dosage*; D002214:Capsules; D005260:Female; D016481:Helicobacter Infections / Q000188:drug therapy; D016480:Helicobacter pylori; D006801:Humans; D064747:Lansoprazole; D008297:Male; D008875:Middle Aged; D009853:Omeprazole / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D010406:Penicillins / Q000008:administration & dosage*; D010437:Peptic Ulcer / Q000188:drug therapy*; D010612:Pharyngitis / Q000139:chemically induced; D013280:Stomatitis / Q000139:chemically induced; D013535:Suspensions
chemical_list: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000897:Anti-Ulcer Agents; D002214:Capsules; D010406:Penicillins; D013535:Suspensions; D064747:Lansoprazole; D000658:Amoxicillin; D009853:Omeprazole